Atlas Trials

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Clinical trial NCT03304288 · UNKNOWN

Trial details

NCT number
NCT03304288
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2017-10-11
Primary completion
2021-01-15
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.